Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"

Pharmacoeconomics. 2019 Aug;37(8):1065-1067. doi: 10.1007/s40273-019-00815-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Indazoles
  • Indoles
  • Ovarian Neoplasms*
  • Phthalazines
  • Piperazines
  • Piperidines
  • United States

Substances

  • Indazoles
  • Indoles
  • Phthalazines
  • Piperazines
  • Piperidines
  • rucaparib
  • niraparib
  • olaparib